{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T09:48:56Z","timestamp":1777888136948,"version":"3.51.4"},"reference-count":14,"publisher":"SAGE Publications","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["PRM"],"published-print":{"date-parts":[[2020,11,23]]},"abstract":"<jats:p>The role of pediatric rehabilitation providers during the Coronavirus Disease 2019 (COVID) pandemic of 2020 highlighted the need for improved knowledge about medications utilized in pediatric patients. Pediatric patients with cerebral palsy who were previously receiving botulinum toxin injections on a regular basis went prolonged periods of time between injections, and patients who have intrathecal baclofen pumps were called in to get refills with different intervals. The medically complex patients treated by rehabilitation providers were limited in the type and scope of care they received, and some may have developed adverse outcomes related to this delay in care. As a Pediatric Physiatrist who has advanced training and significant research experience within the realm of Clinical Pharmacology, I have seen this pandemic demonstrate the Sisyphean challenge of continuing appropriate tone management in patients with cerebral palsy while ensuring those patients with neuromuscular conditions maintain their highest level of function. Both of these clinical problems received significant attention within this issue, which I hope allows providers taking care of these populations a reference point to take to the bedside.<\/jats:p>","DOI":"10.3233\/prm-200026","type":"journal-article","created":{"date-parts":[[2020,11,13]],"date-time":"2020-11-13T10:28:03Z","timestamp":1605263283000},"page":"221-223","source":"Crossref","is-referenced-by-count":2,"title":["Safe and effective medication utilization in pediatric patients requiring rehabilitation services during the Coronavirus pandemic of 2019"],"prefix":"10.1177","volume":"13","author":[{"given":"Matthew","family":"McLaughlin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","reference":[{"issue":"6","key":"10.3233\/PRM-200026_ref1","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1056\/NEJMoa2016638","article-title":"A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19","volume":"383","author":"Boulware","year":"2020","journal-title":"N Engl J Med."},{"issue":"35","key":"10.3233\/PRM-200026_ref2","doi-asserted-by":"publisher","first-page":"1210","DOI":"10.15585\/mmwr.mm6935a4","article-title":"Hydroxychloroquine and Chloroquine Prescribing Patterns by Provider Specialty Following Initial Reports of Potential Benefit for COVID-19 Treatment\u00a0\u2013 United States, January-June 2020","volume":"69","author":"Bull-Otterson","year":"2020","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"10.3233\/PRM-200026_ref3","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2007764"},{"issue":"1","key":"10.3233\/PRM-200026_ref4","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat Commun."},{"issue":"2","key":"10.3233\/PRM-200026_ref5","doi-asserted-by":"publisher","first-page":"e00221","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"mBio."},{"key":"10.3233\/PRM-200026_ref6","doi-asserted-by":"publisher","first-page":"104541","DOI":"10.1016\/j.antiviral.2019.104541","article-title":"Broad spectrum antiviral remdesivir inhibits human endemic and zoonotic deltacoronaviruses with a highly divergent RNA dependent RNA polymerase","volume":"169","author":"Brown","year":"2019","journal-title":"Antiviral Res."},{"key":"10.3233\/PRM-200026_ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021436"},{"issue":"9","key":"10.3233\/PRM-200026_ref9","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1001\/jama.2020.1166","article-title":"Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018","volume":"323","author":"Wouters","year":"2020","journal-title":"JAMA."},{"key":"10.3233\/PRM-200026_ref10","unstructured":"Food and Drug Administration Modernization Act of 1997."},{"issue":"5","key":"10.3233\/PRM-200026_ref11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1001\/jama.297.5.480","article-title":"Economic return of clinical trials performed under the pediatric exclusivity program","volume":"297","author":"Li","year":"2007","journal-title":"JAMA."},{"issue":"4","key":"10.3233\/PRM-200026_ref15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.5863\/1551-6776-19.4.296","article-title":"Evaluation of Off-label Prescribing at a Children\u2019s Rehabilitation Center","volume":"19","author":"Luedtke","year":"2014","journal-title":"J Pediatr Pharmacol Ther."},{"issue":"5","key":"10.3233\/PRM-200026_ref16","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1097\/PHM.0000000000001334","article-title":"Variability of Steady State Oral Baclofen Prescribing Practices in Pediatric Patients With Cerebral Palsy","volume":"99","author":"McLaughlin","year":"2020","journal-title":"Am J Phys Med Rehabil."},{"issue":"3","key":"10.3233\/PRM-200026_ref17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/j.pmrj.2017.08.441","article-title":"Pharmacogenomic Variability of Oral Baclofen Clearance and Clinical Response in Children With Cerebral Palsy","volume":"10","author":"McLaughlin","year":"2018","journal-title":"PM R."},{"issue":"2","key":"10.3233\/PRM-200026_ref18","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1111\/cts.12607","article-title":"Considerations for Implementing Precision Therapeutics for Children","volume":"12","author":"McLaughlin","year":"2019","journal-title":"Clin Transl Sci."}],"container-title":["Journal of Pediatric Rehabilitation Medicine"],"original-title":[],"link":[{"URL":"https:\/\/content.iospress.com\/download?id=10.3233\/PRM-200026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T04:36:37Z","timestamp":1777610197000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/full\/10.3233\/PRM-200026"}},"subtitle":[],"editor":[{"given":"Matthew","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]},{"given":"Christian","family":"Vercler","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2020,11,23]]},"references-count":14,"journal-issue":{"issue":"3"},"URL":"https:\/\/doi.org\/10.3233\/prm-200026","relation":{},"ISSN":["1875-8894","1874-5393"],"issn-type":[{"value":"1875-8894","type":"electronic"},{"value":"1874-5393","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11,23]]}}}